137 related articles for article (PubMed ID: 38016089)
1. INCIDENCE AND RISK FACTORS OF INTRAOCULAR INFLAMMATION AFTER BROLUCIZUMAB TREATMENT IN JAPAN: A Multicenter Age-Related Macular Degeneration Study.
Inoda S; Takahashi H; Maruyama-Inoue M; Ikeda S; Sekiryu T; Itagaki K; Matsumoto H; Mukai R; Nagai Y; Ohnaka M; Kusuhara S; Miki A; Okada AA; Nakayama M; Nishiguchi KM; Takeuchi J; Mori R; Tanaka K; Honda S; Kohno T; Koizumi H; Miyara Y; Inoue Y; Takana H; Iida T; Maruko I; Hayashi A; Ueda-Consolvo T; Yanagi Y
Retina; 2024 Apr; 44(4):714-722. PubMed ID: 38016089
[TBL] [Abstract][Full Text] [Related]
2. Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map.
Khanani AM; Zarbin MA; Barakat MR; Albini TA; Kaiser PK; B G; Agashivala N; Yu JS; Wykoff CC; MacCumber MW
JAMA Ophthalmol; 2022 Jan; 140(1):20-28. PubMed ID: 34817566
[TBL] [Abstract][Full Text] [Related]
3. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.
Monés J; Srivastava SK; Jaffe GJ; Tadayoni R; Albini TA; Kaiser PK; Holz FG; Korobelnik JF; Kim IK; Pruente C; Murray TG; Heier JS
Ophthalmology; 2021 Jul; 128(7):1050-1059. PubMed ID: 33207259
[TBL] [Abstract][Full Text] [Related]
4. Visual outcomes of intraocular inflammation after brolucizumab injection in Japanese patients with neovascular age-related macular degeneration.
Hirono K; Maruyama-Inoue M; Yanagi Y; Kadonosono K
PLoS One; 2024; 19(4):e0302295. PubMed ID: 38635732
[TBL] [Abstract][Full Text] [Related]
5. Short-Term Safety and Efficacy of Intravitreal Brolucizumab Injections for Neovascular Age-Related Macular Degeneration: A Multicenter Retrospective Real-World Study.
Kim DJ; Jin KW; Han JM; Lee SH; Park YS; Lee JY; Lee EK; Lee JS; Kim ST; Shin MH; Lee CS; Jung HH; Jang JY; Kim M; Kim YH; Kim JH; Park KH; Park SJ; Joo K; Ji YS; Sagong M; Woo SJ
Ophthalmologica; 2023; 246(3-4):192-202. PubMed ID: 36720210
[TBL] [Abstract][Full Text] [Related]
6. Real-World Frequency and Management of Ocular Adverse Events in Eyes with Neovascular Age-Related Macular Degeneration Treated with Brolucizumab.
Zubricky R; McCoy J; Donkor R; Miller DG; Sonbolian N; Heaney A; Bilano V; Karcher H; Coney JM
Ophthalmol Ther; 2023 Oct; 12(5):2397-2408. PubMed ID: 37310683
[TBL] [Abstract][Full Text] [Related]
7. Detection and Management of Intraocular Inflammation after Brolucizumab Treatment for Neovascular Age-Related Macular Degeneration.
Bodaghi B; Souied EH; Tadayoni R; Weber M; Ponthieux A; Kodjikian L
Ophthalmol Retina; 2023 Oct; 7(10):879-891. PubMed ID: 37343623
[TBL] [Abstract][Full Text] [Related]
8. Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMD.
Khoramnia R; Figueroa MS; Hattenbach LO; Pavesio CE; Anderesi M; Schmouder R; Chen Y; de Smet MD
Graefes Arch Clin Exp Ophthalmol; 2022 Jun; 260(6):1843-1856. PubMed ID: 34932153
[TBL] [Abstract][Full Text] [Related]
9. Central retinal artery occlusion after intravitreal brolucizumab injection for treatment-naïve neovascular age-related macular degeneration; a case report.
Hong SH; Kim HD
BMC Ophthalmol; 2024 Apr; 24(1):200. PubMed ID: 38679743
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of brolucizumab in neovascular age-related macular degeneration: A multicentre retrospective real-world study.
Kim DJ; Kim DG; Kwak HD; Jang JY; Ji YS; Lee SH; Lee EK; Park KH; Kim JH; Lee JS; Song Y; Kim ST; Shin MH; Kim M; Park SJ; Joo K; Sagong M; Lee CS; Woo SJ
Acta Ophthalmol; 2024 May; ():. PubMed ID: 38706195
[TBL] [Abstract][Full Text] [Related]
11. Clinical features and associated factors of intraocular inflammation following intravitreal brolucizumab as switching therapy for neovascular age-related macular degeneration.
Sotani R; Matsumiya W; Kim KW; Miki A; Yasuda E; Maeda Y; Hara R; Kusuhara S; Nakamura M
Graefes Arch Clin Exp Ophthalmol; 2023 Aug; 261(8):2359-2366. PubMed ID: 36971800
[TBL] [Abstract][Full Text] [Related]
12. Incidence, clinical features, risk factors, and outcomes of Intraocular inflammation following Brolucizumab in Indian eyes - A multicentric study.
Chakraborty D; Mondal S; Sengupta S; Abbas Z; Chandra K; Boral S; Maiti A; Roy S; Mukherjee A; Das A; Chakraborty S; Nag P
Indian J Ophthalmol; 2023 May; 71(5):1979-1985. PubMed ID: 37203069
[TBL] [Abstract][Full Text] [Related]
13. Baseline characteristics associated with the incidence of intraocular inflammation after the intravitreous injection of brolucizumab.
Hoshi K; Kunikata H; Aizawa N; Yasuda M; Okabe T; Takizawa H; Abe T; Nakazawa T
Int Ophthalmol; 2023 Dec; 43(12):4701-4709. PubMed ID: 38044420
[TBL] [Abstract][Full Text] [Related]
14. INTRAOCULAR INFLAMMATION INCIDENCE AFTER INTRAVITREAL BROLUCIZUMAB INJECTION FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
Pakravan P; Patel V; Lai J; Shaheen A; Kalahasty K; Reyes-Capo DP; Chau V; Rosenfeld PJ; Haddock LJ; Schwartz SG; Smiddy WE; Kovach JL; Sridhar J; Flynn HW; Albini TA; Yannuzzi NA
Retina; 2023 Oct; 43(10):1717-1722. PubMed ID: 37320859
[TBL] [Abstract][Full Text] [Related]
15. Real-World Safety Outcomes with Brolucizumab in Neovascular Age-Related Macular Degeneration: Findings from the IRIS® Registry.
Zarbin MA; MacCumber MW; Karcher H; Adiguzel E; Mayhook A; LaPrise A; Bilano VL; Igwe F; Ip MS; Wykoff CC
Ophthalmol Ther; 2024 May; 13(5):1357-1368. PubMed ID: 38520643
[TBL] [Abstract][Full Text] [Related]
16. Clinical Characteristics and Outcomes of Eyes with Intraocular Inflammation after Brolucizumab: Post Hoc Analysis of HAWK and HARRIER.
Singer M; Albini TA; Seres A; Baumal CR; Parikh S; Gale R; Kaiser PK; Lobach I; Feltgen N; Joshi MR; Ziemssen F; Bodaghi B
Ophthalmol Retina; 2022 Feb; 6(2):97-108. PubMed ID: 33971353
[TBL] [Abstract][Full Text] [Related]
17. Brolucizumab in recalcitrant neovascular age-related macular degeneration-real-world data in Chinese population.
Weng CC; Chi SC; Lin TC; Huang YM; Chou YB; Hwang DK; Chen SJ
PLoS One; 2024; 19(4):e0301096. PubMed ID: 38564612
[TBL] [Abstract][Full Text] [Related]
18. Functional Outcomes of Brolucizumab-Induced Intraocular Inflammation Involving the Posterior Segment-A Meta-Analysis and Systematic Review.
Garweg JG; Keiper J; Pfister IB; Schild C
J Clin Med; 2023 Jul; 12(14):. PubMed ID: 37510788
[TBL] [Abstract][Full Text] [Related]
19. MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.
Khanani AM; Brown DM; Jaffe GJ; Wykoff CC; Adiguzel E; Wong R; Meng X; Heier JS;
Ophthalmology; 2022 Sep; 129(9):974-985. PubMed ID: 35537533
[TBL] [Abstract][Full Text] [Related]
20. Sub-Tenon's capsule triamcinolone acetonide injection to prevent brolucizumab-associated intraocular inflammation.
Hikichi T
Graefes Arch Clin Exp Ophthalmol; 2022 Aug; 260(8):2529-2535. PubMed ID: 35235038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
